Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency

Summary

To assess the efficacy of methotrexate in a genetically selected population of patients with advanced colorectal cancer, who have loss of a particular gene, MSH2. The efficacy of methotrexate will be evaluated by the proportion of cases that have a significant response to treatment (objective response rate).

Timeline

Start

2009-02

Primary completion

2014-09

Completion

2014-09

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of recruitment - only 2 patients recruited.”

Drugs

Indications